My Profile

Search abstracts

Lewis Sheiner


2017
Budapest, Hungary



2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
København, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain
   Program
   Abstracts


1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland

Printable version
Thursday June 15
08:00-08:40 Registration and coffee
08:40-09:00 Welcome and Introduction
Oral session I COSTB15 session (1) chair: Leon Aarons
09:00-09:05 Leon Aarons Introduction: COSTB15
09:05-09:25 Mats Karlsson A report on an expert meeting to discuss the role of modelling in Phase I clinical drug development
09:25-10:00 David Giltinan Population PK/PD Modeling in Drug Development: A Case Study
10:00-11:30 Poster and software session I
Oral session II COSTB15 session (2) chair: Rene Bruno
11:30-12:05 Lewis Sheiner Model Evaluation: Some Preliminary Experience with the Posterior Predictive Check
12:05-12:30 France Mentre Validation methods in population pharmacokinetics: a new approach based on predictive distributions with an evaluation by simulation
12:30-14:00 Lunch
Oral session III Paediatrics/Clinical applications chair: Tom Ludden
14:00-14:35 Alison Thomson Population pharmacokinetics in paediatric patients -- the good, the bad and the ugly
14:35-15:00 Rik Schoemaker In search of an optimal furosemide infusion strategy in children after cardiac surgery using modelling and simulation
15:00-15:20 Iñaki f. Trocóniz Pharmacokinetic/pharmacodynamic modeling of the antipyretic effect of two oral formulations of ibuprofen: suspension and effervescent granules
15:20-15:40 Emmanuelle Comets Evaluation of tests based on individual versus population modelling to compare dissolution curves
15:40-16:00 Roberto Gomeni Population pk/pd of craving symptoms in an enforced smoking cessation population: probabilistic and indirect modelling approach
16:00-17:00 Poster and software session II
17:00-17:30 Session honoring Alison Boeckmann
Stuart Beal, Tom Ludden, Pascal Girard, Brigitte Tranchand
20:30- open Social event
Friday June 16
Tutorial chair: France Mentré
08:45-09:30 Stuart Beal Things you may have wanted to ask about the $ESTIMATION record but have been hesitant to ask
Oral session IV chair: France Mentré
09:30-09:50 Eugène Cox Population pharmacodynamic model for count data: application to clinical trial simulations for compound PH2000 for the improvement of the number of satisfying events
09:50-10:10 B. Vrijens The impact of patient compliance in pharmacokinetic/pharmacodynamic studies
10:10-11:45 Poster and software session III
PAGE session chair: David Tudor
11:45-11:55 David Tudor Presentation of next year's PAGE meeting, miscellaneous information and call for new OC members
Oral session V Advances in population analysis chair: David Tudor
11:55-12:25 Paul Williams The Application of Resampling Methods to Population Pharmacokinetics
12:25-12:55 Didier Concordet Checking departure from normality of the random effects
12:55-13:25 Stephen Duffull Optimal design of population pharmacodynamic experiments
13:25-13:45 Sylvie Retout Optimal population designs for enoxaparin pharmacokinetics: evaluation by simulation
13:45-14:00 Closure followed by light lunch